A5012521967- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- Viral gastroenteritis research and epidemiology
- SARS-CoV-2 and COVID-19 Research
- Bacterial Infections and Vaccines
- COVID-19 Clinical Research Studies
- Neonatal Respiratory Health Research
- Hepatitis Viruses Studies and Epidemiology
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Long-Term Effects of COVID-19
- Cystic Fibrosis Research Advances
- Viral Infections and Immunology Research
- Animal Virus Infections Studies
- Emergency and Acute Care Studies
- Antimicrobial Resistance in Staphylococcus
- Delphi Technique in Research
- Streptococcal Infections and Treatments
- Food Allergy and Anaphylaxis Research
- Child and Adolescent Health
- Pharmaceutical studies and practices
- Antibiotic Use and Resistance
- Ear Surgery and Otitis Media
The University of Western Australia
2016-2025
The University of Sydney
2012-2025
The Kids Research Institute Australia
2016-2025
Curtin University
2017-2025
Charles Darwin University
2016-2025
Princess Margaret Hospital for Children
2015-2025
Perth Children's Hospital
2018-2025
Menzies School of Health Research
2016-2025
Sydney Children’s Hospitals Network
2014-2024
Children's Hospital at Westmead
2020-2024
Differentiating bacterial from viral pneumonia is important for guiding targeted management and judicious use of antibiotics. We assessed if clinical characteristics blood inflammatory biomarkers could be used to distinguish pneumonia.Western Australian children (≤17 years) hospitalized with radiologically-confirmed community-acquired were recruited symptoms data collected. C-reactive protein (CRP), white cell counts (WCC) absolute neutrophil (ANC) measured as part routine care. Clinical...
The human rotavirus vaccine was evaluated during an outbreak of G2P[4] infection in central Australia. No overall protective effect against hospitalization demonstrated, raising concerns over the durability protection heterotypic strains.Two and a half years after commencing routine vaccination with vaccine, occurred Vaccine effectiveness P[8]-containing strain (G9P[8]) had been demonstrated previously this setting. This subsequent provided opportunity to evaluate hospitalizations for...
OBJECTIVE: Data on the effectiveness of diphtheria–tetanus–acellular pertussis (DTaP) vaccine in first 4 years life are sparse. We evaluated (VE) 1 and 2 doses DTaP before 6 months age 3 from Australia, where, since 2003, a fourth dose is not given until years. METHODS: matched reported cases aged to 47 between January 2005 December 2009 controls population-based immunization register by date birth region residence. VE number group was calculated as (1 – odds ratio) × 100%. RESULTS: against...
We sought to determine the range and extent of neurologic complications due pandemic influenza A (H1N1) 2009 infection (pH1N1'09) in children hospitalized with influenza.Active hospital-based surveillance 6 Australian tertiary pediatric referral centers between June 1 September 30, 2009, for aged <15 years laboratory-confirmed pH1N1'09.A total 506 pH1N1'09 were hospitalized, whom 49 (9.7%) had complications; median age 4.8 (range 0.5-12.6 years) compared 3.7 (0.01-14.9 those without...
Although recommended for almost a decade, evidence field effectiveness of vaccinating close adult contacts newborn infants against pertussis ("cocooning") is lacking. We evaluated the impact government-funded cocoon program during epidemic in New South Wales, Australia.We matched all Wales laboratory-confirmed cases aged <4 months with onset between April 1, 2009, to March 30, 2011 controls from state birth register by date and area residence. Parental vaccine receipt was self-report, subset...
The outcomes reported in trials coronavirus disease 2019 are extremely heterogeneous and of uncertain patient relevance, limiting their applicability for clinical decision-making. aim this workshop was to establish a core set people with suspected or confirmed 2019.
OBJECTIVES: Respiratory failure, multiple organ shortness of breath, recovery, and mortality have been identified as critically important core outcomes by more than 9300 patients, health professionals, the public from 111 countries in global coronavirus disease 2019 outcome set initiative. The aim this project was to establish measures for these domains trials 2019. DESIGN: Three online consensus workshops were convened four respiratory recovery. SETTING: International. PATIENTS: About 130...
Introduction There has been renewed interest in the therapeutic use of bacteriophages (phages); however, standardised protocols are lacking, and there is a paucity rigorous clinical trial data assessing efficacy. Methods analysis We propose an open-label, single-arm investigating treatment monitoring protocol for phage therapy. Patients included will have exhausted other options control their infection therapy be administered under Australia’s Therapeutic Goods Administration Special Access...
High levels of antimicrobial resistance (AMR) are propagating deaths due to neonatal and paediatric infections globally. This is particular concern in Southeast Asia the Pacific, where healthcare resources constrained access newer agents treat multidrug-resistant pathogens limited. To assess coverage provided by commonly prescribed empiric antibiotic regimens for children low- middle-income countries we built a weighted incidence syndromic combination antibiogram (WISCA), parameterised using...
Indigenous children living in arid Central Australia experience frequent outbreaks of rotavirus gastroenteritis. A widespread outbreak G9 infection occurred several months after introduction the RIX4414 vaccine. We performed a retrospective case-control study to determine vaccine efficacy during outbreak. Two doses provided an estimated 77.7% (95% confidence interval, 40.2%-91.7%) against hospitalization for Vaccine was 84.5% 23.4%-96.9%) confirmed cases infection. Vaccination effective this...
SUMMARY Linked administrative population data were used to estimate the burden of childhood respiratory syncytial virus (RSV) hospitalization in an Australian cohort aged <5 years. RSV-coded hospitalizations extracted for all children years born New South Wales (NSW), Australia between 2001 and 2010. Incidence was calculated as total number new episodes RSV divided by child-years at risk. Mean cost per episode estimated using public hospital weights. The comprised 870 314 children....
Introduction Respiratory pathogens associated with childhood pneumonia are often detected in the upper respiratory tract of healthy children, making their contribution to difficult determine. We aimed determine common adjusting for rates asymptomatic detection inform future diagnosis, treatment and preventive strategies. Methods A case–control study was conducted among children <18 years Perth, Western Australia. Cases were hospitalised radiologically confirmed pneumonia; controls...
In 2017, Australia experienced record influenza notifications. Two surveillance programs combined to summarize the epidemiology of hospitalized in children and report on vaccine effectiveness (VE) context a limited nationally funded vaccination program.Subjects were prospectively recruited (April-October 2017). Case patients aged ≤16 years admitted 11 hospitals with an acute respiratory illness laboratory-confirmed influenza. Controls tested negative for VE estimates calculated using...
Abstract Objective To determine whether disrupting the renin angiotensin system with receptor blockers will improve clinical outcomes in people covid-19. Design CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. Setting 17 hospital sites India and Australia. Participants were at least 18 years old, previously untreated blockers, laboratory confirmed diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who had been admitted to...
There is a recognized unmet need for clinical trials to provide evidence-informed care infants, children and adolescents. This Special Communication outlines the capacity of 3 distinct trial design strategies, sequential, parallel, unified adult-pediatric bayesian adaptive design, incorporate into transform this current state evidence inequity. A whole-of-life demonstrated through Staphylococcus aureus Network Adaptive Platform (SNAP) trial.